Success Metrics

Clinical Success Rate
100.0%

Based on 5 completed trials

Completion Rate
100%(5/5)
Active Trials
1(10%)
Results Posted
20%(1 trials)

Phase Distribution

Ph not_applicable
2
20%
Ph phase_1
1
10%
Ph phase_2
5
50%
Ph phase_4
2
20%

Phase Distribution

1

Early Stage

5

Mid Stage

2

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
1(10.0%)
Phase 2Efficacy & side effects
5(50.0%)
Phase 4Post-market surveillance
2(20.0%)
N/ANon-phased studies
2(20.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

5 of 5 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

10

all time

Status Distribution
Active(2)
Completed(5)
Other(3)

Detailed Status

Completed5
unknown3
Recruiting1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
1
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (10.0%)
Phase 25 (50.0%)
Phase 42 (20.0%)
N/A2 (20.0%)

Trials by Status

recruiting110%
completed550%
not_yet_recruiting110%
unknown330%

Recent Activity

1 active trials
Showing 5 of 10
recruitingphase_2

Teniposide, Cisplatin and Serplulimab for Treatment of ES-SCLC, a Randomized Controlled Study

NCT07583511
not_yet_recruitingphase_2

Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSL

NCT07185373
unknownnot_applicable

Teniposide Incorporating Bu/Cy Conditioning Regimen for HLH With Central Nervous System Involvemen

NCT06048107
completedphase_2

Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma

NCT01700946
completedphase_4

German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003)

NCT00198991
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT07583511Phase 2

Teniposide, Cisplatin and Serplulimab for Treatment of ES-SCLC, a Randomized Controlled Study

Recruiting
NCT07185373Phase 2

Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSL

Not Yet Recruiting
NCT06048107Not Applicable

Teniposide Incorporating Bu/Cy Conditioning Regimen for HLH With Central Nervous System Involvemen

Unknown
NCT01700946Phase 2

Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma

Completed
NCT00198991Phase 4

German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003)

Completed
NCT00853008Phase 4

Treatment of High Risk Adult Acute Lymphoblastic Leukemia

Completed
NCT00002531Phase 2

Combination Chemotherapy in Treating Adults With Acute Lymphocytic Leukemia

Unknown
NCT00343369Not Applicable

Combination Chemotherapy in Treating Young Patients With Acute Lymphoblastic Leukemia

Unknown
NCT00004916Phase 1

Ifosfamide, Teniposide, and Paclitaxel in Treating Patients With Relapsed Non-Hodgkin's Lymphoma

Completed
NCT00004231Phase 2

Combination Chemotherapy, Bone Marrow or Peripheral Stem Cell Transplantation, and/or Biological Therapy in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma

Completed

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10